Your browser does not support JavaScript!
:::
:::
鄭恩加教授
 

鄭 恩 加 (Ann-Joy Cheng)

學歷

美國德州大學安德生癌症中心腫瘤生物學博士

任課科目

臨床化學、分子生物學、細胞生物學、醫用生物技術學、生技學研究實驗

研究專長

腫瘤生物學、.細胞分子生物學、生物化學 、醫學生物技術

辦公室分機

5085

實驗室分機

5216

個人網頁

轉譯癌症研究室

E-mail

annjoycheng@gap.cgu.edu.tw

研究方向及研究室特色(Lab & Research Interest)

       我們轉譯癌症實驗室以研究臨床相關的癌症議題為主,並且致力於本土頭頸癌之研究。頭頸癌包含口腔癌、咽喉癌,是個本土性高的惡性疾病。在台灣,頭頸癌是十大癌症之一,是近十年來有好發率攀升最高之癌症,且因頭頸癌好發在中年男性,因此對家庭及社會無形中造成相當大的影響,因此,對頭頸癌致癌因子研究之急切性,可說是刻不容緩。以流行病學的角度看,西方國家的頭頸癌占所有惡性腫瘤約3%,台灣占約10%,而好發最高的印度占約30%,這些差異,除了族群基因體本身的因素外,可能與所接觸的致癌因子以關,如,印度地區常嚼食雪茄及成熟檳榔,台灣病患常是煙、酒、青檳榔合併習慣性使用,而西方國家並無嚼食檳榔的習慣。因為流行病學、致癌因子及臨床表徵上的差異極大,台灣頭頸癌之致癌機轉也可能有其區域獨特性,因此本土的頭頸癌必須自己來研究並解決。

       頭頸癌依各部位與個別狀況,在臨床治療上,常結合手術與放射或化學治療,各專科醫師相互配合並分行其職,而我們實驗室與臨床醫師們共同組成長庚頭頸癌研究團隊,進行臨床相關的議題研究,研究內容含致癌因子機制、癌症標誌研發、癌症分子病理機轉,到治療預後評估,如癌細胞侵犯轉移、放化療抵抗性等。為達成這些目標,我們建立了數株本土頭頸癌細胞株,並高侵犯性細胞子株、抗放射子株、抗化藥子株、慢性檳榔暴露子株等,並運用基因蛋白質體學等方法,全面性探討導致這些細胞表徵的基因轉譯圖誌,再以生物資訊和細胞動物模式,探討分子間的網絡途徑和基因功能,並進行臨床相關性分析,以期系統性探討頭頸癌癌化之分子機制。目前我們已發現數個分子,首先報導與頭頸癌相關,如DSG3、Grp78、Gp96等,分別調控細胞侵犯轉移、調控癌幹細胞形成、或扮演抗放化療的角色等。未來,期望這些結果不只在癌症醫學知識有所貢獻,更能研發出有效輔助診治頭頸癌之工具,供臨床使用,使頭頸癌得以控制,增進台灣及國際社會的健康福祉。

論文與著作(Publication)

A. 論文

1.  Li YL, Chang JT, Lee LY, Fan KH, Lu YC, Li YC, Chiang CH, Chen HY, Cheng AJ*. (2017.01) GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating cellular reactive oxygen species via a SMAD-associated signaling pathway. Oncotarget 2017, 8: 1508-1528. doi: 10.18632/oncotarget.13649. PMID: 27903972

2. Chiang CH, Wu CC, Lee LY, Li YC, Liu HP, Hsu CW, Lu YC, Chang JT, Cheng AJ*. (2016, 09) Proteomics analysis reveals involvement of Krt17 in areca nut – induced oral carcinogenesis. J Proteome Res 2016, 15: 2981-2997. doi: 10.1021/acs.jproteome.6b00138. PMID: 27432155.

3.  Chao YK, Peng TL, Chuang WY, Yeh CJ, Li YL, Lu YC, Cheng AJ*. (2016.07) Transketolas serve a poor prognosticator in esophageal cancer by promoting cell invasion via epithelial – mesenchymal transition. J Cancer 2016, 7: 1408-1811.

4.  Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS, Chen JS, Cheng AJ*. (2016.05) miR-196, an emerging cancer biomarker for digestive tract cancers. J Cancer 2016, 7(6): 650-655. doi: 10.7150/jca.13460. PMID: 27076845.

5.   Li YC, Chang JT, Chiu C, Lu YC, Yi YL, Chiang CH, You GR, Lee LY, Cheng AJ*. (2016.03) Areca nut contributes to oral malignancy through facilitating the conversion of cancer stem cells. Mol Carcinog 2016, 55: 1012-1023. doi: 10.1002/mc.22344. PMID: 26087469.

6.   Cheng CW, Hsiao JR, Fan CC, Lo YK, Tzen CY, Wu LW, Fang WY, Cheng AJ, Chen CH, Chang IS, Jiang SS, Chang JY, Lee AY. (2016.05) Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial- mesenchymal transition in oral squamous cell carcinoma. Mol Carcinog 2016, 55(5): 499-513. doi: 10.1002/mc.22297. PMID: 25728212.

7.  Martel J, Wu CY, Hung CY, Wong TY, Cheng AJ, Cheng ML, Shiao MS, Young JD. (2016.03) Fatty acids and small organic compounds bind to mineralo-organic nanoparticles derived from human body fluids as revealed by metabolomic analysis. Nanoscale 2016, 8(10): 5537-5545. doi: 10.1039/c5nr08116e. PMID: 26818428

8.  Lee CH, Pank KL, Tang YC, Tsai MH, Cheng AJ, Shen MY, Cheng YM, Huang TT, Lin P. (2015.09) LDOC1 silenced by cigarette exposure and involved in oral neoplastic transformation. Oncotarget 2015, 6: 25188-25201. doi: 10.18632/oncotarget.4512. PMID: 26317789.

9.   Lee LY, Chen YJ, Lu YC, Liao CT, Chen IH, Chang JTC, Huang YC, Chen WH, Huang CC, Tsai CY, Cheng AJ*. (2015.09) Fascin is a circulating tumor marker for head and neck cancer as determined by a proteomic analysis of interstitial fluid from the tumor microenvironment. Clin Chem Lab Med 2015, 53: 1031-1641. doi: 10.1515/cclm-2014-1016. PMID: 25781684.

10.  Lu YC, Chang JT, Huang YC, Huang CC, Chen WH, Lee LY, Huang BS, Chen YJ, Li HS, Cheng AJ*. (2015.02) Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer. Clin Biochem 2015, 48: 115-121. doi: 10.1016/j.clinbiochem.2014.11.020. PMID: 25485932.

11. Lu YC, Chang JT, Liao CT, Kang CJ, Huang SF, Chen IH, Huang CC, Huang YC, Chen WH, Tsai CY, Wang HM, Yen TC, You GR, Chiang CH, Cheng AJ*. (2014.09) OncomiR-196 promotes an invasive phenotype in oral cancer through the NEM4-JNK-TIMP1-MMP signaling pathway. Mol Cancer 2014, 13:218. doi:10.1186/1476-4598-13-218. PMID: 25233933.

12.  Peng SC, Liao CT, Peng CH, Cheng AJ, Chen SJ, Huang CG, Hsieh WP, Yen TC. MicroRNA miR-218, mir-125b, and let-7g predict prognosis in patients with oral cavity squamous cell carcinoma. (2014.07) PLoS One 2014, 9: e102403. doi: 10.1371/journal.pone.0102403. PMID: 25050624.

13. Lu YC, Cheng AJ*. (2014.05). Pathological function and clinical significance of microRNA-10b in cancer. Cancer Sci Res Open Access 1(2): 1-5.

14. Yen YC, Shiah SG, Chu HC, Hsu YM, Hsiao JR, Chang JY, Hung WC, Liao CT, Cheng AJ, Lu YC, Chen YW. (2014.01) Reciprocal regulation of microRNA-99a and insulin-like growth factor I receptor signaling in oral squamous cell carcinoma cells. Mol Cancer 2014, 13:6. doi:10.1186/1476-4598-13-6, PMID: 24410957.

15.  Huang WC, Chan SH, Jang TH, Chang JW, Ko YC, Yen TC, Chiang SL, Chiang WF, Shieh TY, Liao CT, Juang JL, Wang HC, Cheng AJ, Lu YC, Wang LH. (2014.02) miRNA-491-5p and GIT1 Serve as Modulators and Biomarkers for Oral Squamous Cell Carcinoma Invasion and Metastasis. Cancer Res 2014, 74:751-64. doi:10.1158/0008-5472.CAN-13-1297. PMID: 24335959.

16. Chiu CC, Lee LY, Li YC, Chen YJ, Lu YC, Li YL, Wang HM, Chang JTC, Cheng AJ*. (2013.11) Grp78 as a therapeutic target for refractory head-neck cancer with CD24-CD44+ stemness phenotype. Cancer Gene Ther 2013, 20: 606-615. doi: 10.1038/cgt.2013.64. PMID: 24201869.

17.  Lee CH, Wong TS, Chan JY, Lu SC, Lin P, Cheng AJ, Chen YJ, Chang JS, Hsiao SH, Leu YW, Li CI, Hsiao JR, Chang JY. (2013.07) Epigenetic regulation of the X-linked tumor suppressors BEX1 and LDOC1 in oral squamous cell carcinoma. J Pathol 2013, 230: 298-309. doi: 10.1002/path.4173.

18.  Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, et al. (2013.06) Identification of targetable EGFR gene fusions in diverse cancers. Cancer Discov 2013, 3:636-647. doi: 10.1158/2159-8290.CD-13-0050. PMID: 23558953.

19.  Jian SL, Hsieh HY, Liao CT, Yen TC, Nien SW, Cheng AJ, Juang JL. (2013.06) Ga12 drives invasion of oral squamous cell carcinoma through up-regulation of proinflammatory cytokines. PLoS One 2013, 8: e66133. doi: 10.1371/journal.pone.0066133. PMID: 23762476.

20. Chen YJ, Lee LY, Chao YK, Chang JT, Lu YC, Li HF, Chiu CC, Li YL, Chiou JF, Cheng AJ*. (2013.05) DSG3 facilitates cancer cell growth and invasion through the DSG3- plakoglobin - TCF/LEF - myc / cyclinD1 / MMP signaling pathway. PLoS One 2013, 8:e60488. doi: 10.1371/journal.pone.0064088. PMID: 23737966.

21.  Le QT, Zhang Q, Cao H, Cheng AJ, Pinsky BA, Hong RL, Chang JT, Wang CW, Tsao KC, Lo YD, Lee NY, Ang KK, Chan AT, Chan KA. (2013.04) An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus (EBV) DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. Clin Cancer Res 2013, 19: 2208-2015. doi: 10.1158/1078-0432.CCR-12-3702. pMID: 23459720.

22. Huang SF, Li HF, Liao CT, Wang HM, Chen IH, Chang JTC, Chen YJ, Cheng AJ*. (2012. 11) Association of HPV infection with second primary tumors in early staged oral cavity cancer. Oral Disease 2012, 18: 809-815. doi: 10.1111/j.1601-0825.2012.01950.x. PMID: 22747969.

23.  Tsai JP, Lee MH, Hsu SC, Chen MY, Liu SJ, Chang JT, Liao CT, Cheng AJ, Chong P, Chu CL, Shen CR, Chen HW. (2012.08) CD4+ T cells disarm or delete cytotoxic T lymphocytes under IL-17 polarizing conditions.  J Immunol 2012, 189: 1671-1679.  doi: 10.4049/jimmunol.1103447. PMID: 22798680.

24.  Lu YC, Chen YJ, Wang HM, Tsai CY, Chen WH, Huang YC, Fan KH, Tsai CN, Huang SF, Kang CJ, Chang JT, Cheng AJ*. (2012.04) Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res 2012, 5:665-674. doi: 10.1158/1940-6207.CAPR-11-0358. PMID: 22318752.

25.  Chao YK, Chuang WY, Yeh CJ, Wu YC, Liu YH, Hsieh MJ, Cheng AJ, Hsueh C, Liu HP (2012, 02). Prognostic significance of high podoplanin expression after chemoradiotherapy in esophageal squamous cell carcinoma patients. J Surg Oncol 2012, 105:183-188. doi: 10.1002/jso.22068. PMID: 22213642.

26.   Lin CY, Lin TY, Wang HM, Huang SF, Fan KH, Liao CT, Chen IH, Lee LY, Li YL, Chen YJ, Cheng AJ*, Chang JT. (2011.11) GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy. Radiat Oncol 2011, 6: 136-143. doi: 10.1186/1748-717X-6-136. PMID: 21992474.

27.  Peng CH, Liao CT, Peng SC, Chen YJ, Cheng AJ, Juang JL, Tsai CY, Chen TC, Chuang YJ, Tang CY, Hsieh WP, Yen TC. (2011.06) A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PLoS One. 2011, 6:e23452. doi: 10.1371/journal.pone.0023452. PMID: 21853135.

28.  Chiu CC, Lin CY, Lee LY, Chen YJ, Lu YC, Wang HM, Liao CT, Chang JT, Cheng AJ*. (2011, 07) Molecular chaperones as a common set of proteins that regulate the invasion phenotype of head and neck cancer. Clin Cancer Res 2011, 17: 4629-4641. doi: 10.1158/1078-0432.CCR-10-2107. PMID: 21642380.

29.   Chen YJ, Liao CT, Chen PJ, Lee LY, Li YC, Chen IH, Wang HM, Chang JTC, Chen LJ, Yen TC, Tang CY, Cheng AJ*. (2011, 3) Down-regulation of Ches1 and other novel genes in oral cancer cells chronically exposed to areca nut extract. Head Neck 2011, 33: 257-266. doi: 10.1002/hed.21442.. PMID: 20848451.

30.  Chang JTC, Kuo TF, Chen YJ, Chiu CC, Lu YC, Li HS, Wang HM, Shen CR, Cheng AJ*. (2010, 12) Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers. Cancer Gene Ther 2010, 17: 827-836. doi: 10.1038/cgt.2010.38. PMID: 20885450.

31.  Lin TY, Chang JTC, Wang HM, Chan SH, Chiu CC, Lin CY, Fan KH, Liao CT, Chen IH, Liu TZ, Li HF, Cheng AJ*. (2010.09) Proteomics of the radioresistant phenotype in head-and-neck cancer: GP96 as a novel prediction marker and sensitizing target for radiotherapy. Int J Radiat Oncol Biol Phys 2010, 78: 246-256. doi: 10.1016/j.ijrobp.2010.03.002. PMID: 20615631.

32.  Lin CY, Chen WH, Liao CT, Chen IH, Chiu CC, Wang HM, Yen TC, Lee LY, Chang JT, Cheng AJ*. (2010, 8) Positive association of Grp78 during oral cancer progression and the prognostic value in oral precancer lesions. Head Neck 2010, 32: 1028-1039.  doi: 10.1002/hed.21287. PMID: 19953611.

33.      Liao CT, Wang HM, Chang JT, Lin CY, Ng SH, Huang SF, Chen IH, Hsueh C, Lee LY, Lin CH, Cheng AJ, Yen TC. (2010.06) Influence of pathological nodal status and maximal standardized uptake value of the primary tumor and regional lymph nodes on treatment plans in patients with advanced oral cavity squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2010; 77: 421-429. doi: 10.1016/j.ijrobp.2009.05.002. PMID: 20457351.

34.   Wu YH, Wang HM, Chen HW, Lin CY, Chen YE, Fan KH, Huang SF, Chen IH, Liao CT, Cheng AJ, Chang JT. (2010, 3) Hypothyroidism after radiotherapy for nasopharyngeal cancer patients. Int J Radiat Oncol Biol Phys 2010, 76: 1133-1139. doi: 10.1016/j.ijrobp.2009.03.011. PMID: 19596170.

35.  Chao YK, Yeh CJ, Chuang WY, Fan KH, Hsieh MJ, Chu Y, Cheng AJ, Liu HP. (2009, 12) Prognostic significance of immunohistochemically detected lymph node micrometastases in pT0N0 esophageal squamous cell carcinoma. J Surg Oncol 2009, 100: 559-562.

36.  Kang CJ, Chen YJ, Liao CT, Wang HM, Chang JT, Lin CY, Lee LY, Wang TH, Yen TC, Shen CR, Chen IH, Chiu CC, Cheng AJ*. (2009, 11) Transcriptome profiling and network pathway analysis of genes associated with invasive phenotype in oral cancer. Cancer Lett 2009, 284: 131-140.

37.   Liao CT, Chang JT, Wang HM, Ng SH, Huang SF, Chen IH, Hsueh C, Lee LY, Lin CH, Cheng AJ, Yen TC. (2009, 11) Preoperative [(18)F]-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapse. Eur J Nucl Med Mol Imaging 2009, 36: 1783- 1793.

38.   Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, Yen TC. (2009, 6) Preoperative [18F]fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 2009, 74:1054-1061.

39.   Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, See LC, Yen TC. (2009, 3) Pretreatment primary tumor SUVmas measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 2009, 73: 764-771.

40.   Liao CT, Huang SF, Chen IH, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Cheng AJ, Yen TC. (2009, 1) Risk stratification of patients with oral cavity squamous cell carcinoma and contralateral neck recurrence following radical surgery. Ann Surg Oncol 2009, 16: 159-170.

41.   Chiu CC, Lin CY, Lee LY, Chen YJ, Kuo TF, Chang JTC, Liao CT, Wang HM, Yen TC, Shen CR, Liao SK, Cheng AJ*. (2008, 9) Glucose-regulated protein 78 regulates multiple malignant phenotypes in head-neck cancer and may serve as a molecular target of therapeutic intervention. Mol Cancer Ther 2008, 7: 2788-2797.

42.   Liao CT, Huang SF, Chen IH, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Cheng AJ, Yen TC. (2008, 8) When does skin excision allow the achievement of an adequate local control rate in patients with squamous cell carcinoma involving the buccal mucosa? Ann Surg Oncol 2008, 15: 2187-2194.

43.   Chen YJ, Chang JTC, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF, Cheng AJ*. (2008, 8) Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci 2008, 99: 1507-1514.

44.   Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, See LC, Yen TC. (2008, 6) Does adjuvant radiation therapy improve outcome in pT1-3N0 oral cavity cancer with tumor-free margins and perineural invasion? Int J Radiat Oncol Biol Phys 2008, 71: 371-376.

45.   Lin CY, Lee LY, Huang SF, Kang CJ, Fan KH, Wang HM, Chen EY, Chen IH, Laio CT, Cheng AJ, Chang JT. (2008, 4) Treatment outcome of combined modalities for buccal cancer: unilateral or bilateral neck radiation? Int J Radiat Oncol Biol Phys 2008, 70: 1373-1381.

46.   Huang SF, Kang CJ, Lin CY, Fan KH, Yen TC, Wang HM, Chen IH, Liao CT, Cheng AJ, Chang JT. (2008, 3) Neck treatment of patients with early stage oral tongue cancer: comparison between observation, supraomohyoid dissection, and extended dissection. Cancer 2008, 112: 1066-1075.

47.   Liao CT, Chang JT, Wang HM, NgSH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, Yen TC. (2008, 3) Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol 2008, 15: 912-922.

48.   Liao CT, Chang JT, Wang HM, NgSH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, Yen TC. (2008, 1) Salvage therapy in relapsed squamous cell carcinoma of the oral cavity: How and when? Cancer 2008, 112: 94-103.

49.   Lee LA, Cheng AJ, Fang TJ, Huang CG, Liao CT, Chang JT, Li HY. (2008, 1) High incidence of malignant transformation of laryngeal papilloma in Taiwan. Laryngoscope 2008, 118: 50-55.

50.  Chen YJ, Cheng AJ*. (2007, 12) Desmosome proteins play roles in carcinogenesis. J Stomatol Invest 2007, 1: 69-71.

51.   Chang JT, Chen CJ, Lin YC, Chen YC, Lin CY, Cheng AJ. (2007, 9) Health-related quality of life and patient satisfaction after treatment for breast cancer in northern Taiwan. Int J Radiat Oncol Biol Phys 2007, 69: 49-53.

52.   Chang JTC, Chan SH, Lin CY, Lin TY, Wang HM, Liao CT, Wang TH, Lee LY, Cheng AJ*. (2007, 8) Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol Cancer Ther 2007, 6: 2271-2279.

53.   Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, Yen TC. (2007, 8) Survival in squamous cell carcinoma of the oral cavity: differences between pT4 N0 and other stage IVA categories. Cancer 2007, 110: 564-571.

54.   Chen YJ, Chang JT, Lee Ly, Wang HM, Liao CT, Chiu CC, Chen PJ, Cheng AJ*. (2007, 1) DSG3 is over- expressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. Oncogene 2007, 26: 467-476.

55.   Fan KH, Lin CY, Kang CJ, Huang SF, Wang HM, Chen EY, Chen IH, Liao CT, Cheng AJ, Chang JT. (2007, 2) Combined-modality treatment for advanced oral tongue squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007, 67: 453-461.

56.   Liao CT, Kang CJ, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Cheng AJ, Chen IH, Huang SF, Yen TC. (2007, 2) Survival of second and multiple primary tumors in patients with oral cavity squamous cell carcinoma in the betel quid chewing area. Oral Oncol 2007, 43: 811-819.

57.   Chang JTC, Chen LC, Wei SY, Chen YJ, Wang HM, Liao CT, Chen IH, Cheng AJ*. (2006, 12) Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry - plasma peptidomes from nasopharyngeal cancer patients for example. Clin Biochem 2006, 39: 1144-1151.

58.   Yen TC, Lin CY, Wang HM, Huang SF, Liao CT, Kang CJ, Ng SH, Chan SC, Fan KH, Chen IH, Lin WJ, Cheng AJ, Chang JT. (2006, 8) (18)F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 65: 1307-1341.

59. Chang JT, Lu YC, Chen YJ, Tseng CP, Chen YL, Fang CW, Cheng AJ*. (2006, 3) hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cells. Br J Cancer 2006, 94:870-874.

60.  Cheng AJ*, Chen LC, Chien KY, Chen JY, Chang JTC, Wang HM, Liao CT, Chen IH. (2005, 12) Oral cancer plasma tumor marker identified with bead-based affinity fractionated proteomic technology. Clin Chem 2005, 51:2236-2244.

61.   Chang JT, Huei-Ting Yang, Wang TCV, Cheng AJ*. (2005, 11) Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells. Mol Carcinog 2005, 44:183-192.

62.   Chang JT, Lin CY, Chen TM, Kang CJ, Ng SH, Chen IH, Wang HM, Cheng AJ, Liao CT. (2005, 10) Nasopharyngeal carcinoam with cranial nerve palsy: the importance of MRI fro radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63:1354-1360.

63.  Chang JT, Chang KW, Chen WH, Wang HM, Hsu YM, Yung BYM, Chen IH, Liao CY, Chen TM, Hsieh LL, Cheng AJ*. (2005, 5) Identification of differentially expressed genes in oral squamous cell carcinoma (OSCC): over-expression of NPM, CDK1, NDRG1 and under- expression of CHES1. Int J Cancer 2005, 114: 942-949.

64.   Hsieh LL, Huang TH, Chen IH, Liao CT, Wang HM, Lai CH, Liou SH, Chang JT, Cheng AJ. (2005, 1) p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Br J Cancer 2005, 92: 30-35.

65.  Tsui KH, Cheng AJ, Chang PE, Pan TL, Yung BY. (2004, 10) Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology 2004, 64: 839-844.

66.  Chang JT, Wong FW, Liao CT, Chen IH, Wang HM, Cheng AJ*. (2004, 7) Enzyme immunoassay for autoantibody to serum survivin and its finding in head and neck cancers. Clin Chem 2004, 50: 1261-1264.

67. Liao CT, Chang JT, Wang HM, Chen IH, Lin CY, Chen TM, Hsieh LL, Cheng AJ*. (2004, 6) Telomerase as an independent prognostic factor in head and neck squamous cell carcinoma. Head Neck 2004, 26: 504-512.

68.  Liao CT, Chen IH, Chang JT, Wang HM, Hsieh LL, Cheng AJ*. (2003, 9) Lack correlation of betel nut, tobacco smoking or alcohol consumption with telomerase activity and the severity of oral cancer. Chang Gung Med J 2003, 26: 637-645.

69.  Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Chang AJ*. (2003, 8) Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area. Brit J Cancer 2003, 89: 681-686.

70.  Hsieh LL, Chien HT, Chen IH, Liao CT, Wang HM, Jung SM, Wang PF, Chang JT, Chen MC, Cheng AJ. (2003, 5) The XRCC1 399Gln polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 2003, 12: 439-443.

71.  Lin YC, Chou YHW, Liao IC, and Cheng AJ*. (2003, 2) The expression of mammaglobin mRNA in metastatic breast cancer patients as an adjunct to serum tumor markers. Cancer Letters 2003, 191: 93-99.

72. Lin YC, Chen SC, Hsueh S, Lo YF, Chow-Wu YH, Liaw IC, and Cheng AJ. (2003, 1) Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients. Cancer Sci 2003, 94: 99-102.

73. Chang JT, Chen IH, Liao CT, Wang HM, Hsu YM, Hung KF, Lin CJ, Hsieh LL and Cheng AJ*. (2002, 11) A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem 2002, 35: 591-596.

74.  Tseng CP, Cheng AJ, Chang JTC, Tsehg CH, Wang HM, Liao CT, Chen IH, Tseng KC (2002, 11). Quantitative analysis of multidrug-resistance mdr1 gene expression in head and neck cancer by real-time RT-PCR. Jpn J Cancer Res 2002, 93: 1230-1236.

75. Chang JT, Chen YL, Yang HT, Chen CY, and Cheng AJ*. (2002, 7) Differential regulation of telomerase activity by six telomerase subunits. Eur J Biochem 2002, 269: 3442-3450.

76. Chang KW, Kao SY, Tzeng RJ, Liu CJ, Cheng AJ, Yang SC, Wong YK, and Lin SC. (2002, 3) Multiple molecular alterations of FHIT in betel-associated oral carcinoma. J Pathol 2002, 196: 300-306.

77.  Hsieh LL, Wang PF, Chen IH, Liao CT, Wang HM, Chen MC, Chang TC, and Cheng AJ. (2001, 9) Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese. Carcinogenesis 2001, 22: 1497-1503.

78.  Cheng AJ, Chiu DT-Y, See L-C, Liao C-T, JT Chang. (2001, 5) Poor prognosis in nasopharyngeal cancer patients with low glucose-6-phosphate-dehydrogenase activity. Jpn J Cancer Res 2001, 92: 576-581.

79.  Chang JTC, Chen CC, Lee SH, Ho JU, Cheng AJ, Hong JH. (2000, 12) Comparison of treatment plans for nasopharyngeal carcinoma: bil-lateral opposing, 3D conformal and intensity modulated radiotherapy. Therapeutic Radiol Oncol 2000, 7: 267-274.

80.  Chang JTC, Liao C-T, Jung S-M, Wang TV, See LC and Cheng AJ*. (2000, 6) Telomerase activity is frequently found in metaplastic and malighant human nasopharyngeal tissues. Brit J Cancer 2000, 82: 1946-1951.

81.  Yeh T-A, Cheng AJ, Chen T-C, Jan Y-Y, Hung T-L, Jeng L-B, Chen M-F, Wang T-CV. (1999, 12) Telomerase activity is an useful marker to distinguish malignant pancreatic cystic tumor from benign neocysts and pseudocysts. J Surg Res 1999, 87: 171-177.

82.  Cheng AJ, Tang R, Wang JY, Chang JT, and Wang TV. (1999, 3) Polymerase chain reaction-based enzyme immunoassay for quantitation of telomerase activity: application to colorectal cancers. Jpn J Cancer Res 1999, 90: 280-285.

83.  Tang R, Cheng AJ, Wang J-Y, and Wang TV. (1998, 9) Close correlation between telomerase expression and adenomatous polyp progression in multistep colorectal carcinogenesis. Cancer Res 1998, 58: 4052-4054.

84.  Cheng AJ, Lin LD, Chang JT and Wang TV. (1998, 6) Telomerase activity in benign and malignant human thyroid disorders. Brit J Cancer 1998, 77: 2177-2180.

85. Cheng AJ, Wang JC and Van Dyke MW. (1998, 6) Self-association of G-rich oligodeoxy- ribonucleotides under conditions promoting purine-motif triplex formation. Antisense Nucleic Acid Drug Dev 1998, 8:215-225.

86.  Liu Y-H, Cheng A-J, Wang TV. (1998, 4) An involvement of recF, recO and recR genes in UV radiation mutagenesis of Escherichia coli. J Bacteriol 1998, 180: 1766-1770.

87.  Cheng AJ, Tang R, Wang JY, See LC and Wang TV. (1998, 2) Possible role of telomerase activation in the cancer predisposition of patients with hereditary nonpolyposis colorectal cancers. J Natl Cancer Inst 1998, 90: 316-321.

88.  Ku W-C, Cheng AJ, and Wang TV. (1997, 12) Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem Biophy Res Commun 1997, 241: 730-736.

89.  Cheng AJ, and Van Dyke MW. (1997, 9) Oligodeoxyribonucleotide length and sequence effects on intramoleclar and intermolecular G-quartet formation. Gene 1997, 197: 253-260.

90. Cheng AJ, Liao S-K, Chow S-K, Chen J-K and Wang TV. (1997, 8) Differential inhibition of telomerase activity during induction of differentiation in hematopoietic, melanoma and glioma cells in culture. Biochem Biophy Res Commun 1997, 237: 438-444.

91. Cheng AJ, Chang JC, Juan G, and Liu T-Z. (1997) Diagnostic efficacy of a monoclonal antibody-based sandwich enzyme linked immunosorbent assay procedure for quantitation of prostatic acid phosphatase. J Biomed Lab Sci 1997, 9: 22-27.

92. Cheng AJ, Lam K-W, Liu M, and Liu T-Z. (1995) Development of a moloclonal antibody-based enzyme linked immunosorbent assay for the quantitation of prostatic acid phosphatase. J Biomed Lab Sci 1995, 7: 91-96.

93.  Cheng AJ, and Van Dyke MW. (1994, 11) Oligodeoxyribonucleotide length and sequence effects on intermolecular purine-purine-pyrimidine triple-helix formation. Nucleic Acids Res 1994, 22: 4742-4747.

94.  Cheng AJ, and Van Dyke MW. (1993, 12) Monovalent cation effects on intermolecular purine-purine- pyrimidine triple-helix formation. Nucleic Acides Res 1993, 21: 5630-5635.

 

*Corresponding author

B.  書籍/書籍章節

  1. 醫學分子檢驗,第13蛋白質體學及腫瘤胞至蛋白的研發。(陳盈汝、鄭恩加)五南出版社。2009第一版。

  1. 臨床化學原理、步驟與關連性。合計圖書出版社。(編輯:趙啟淵。監修魏正舒、鄭恩加、沈武訓、顏秀娟)。合計圖書出版社。2003第一版。

  2. 通識版生物技術,第5生物技術在臨床診斷上之應用。中華民國教育部發行。(趙崇義、鄭恩加)1998第一版。

C.   專利

  1. Cheng AJ, Chiu CC, Chang JT. Specific Grp78 expression- inhibition RNAi sequence, medicine thereof and method thereof - a method for head and neck cancer. United States Patent. (Patent #: US 7,825,100 B2) ( Patent date: Nov 2, 2010)

  1. Cheng AJ, Chiu CC, Chang JT. Specific Grp78 expression- inhibition RNAi sequence, medicine thereof and method thereof - specific Grp78-RNAi sequence. United States Patent. (Patent #: US 7,829,695 B2) ( Patent date: Nov 9, 2010)

  2. Cheng AJ, Chen YJ, Chang JT. Methods on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degrees of cancer, serving as a molecular target and using RNA jamming sequence on inhibition- specific of DSG3 expression – a suppression method. United States Patent. (Patent #: US 7,622,456 B2) ( Patent date: Nov 24, 2009)

  3. Cheng AJ, Chen YJ, Chang JT. Methods on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degrees of cancer, serving as a molecular target and using RNA jamming sequence on inhibition- specific of DSG3 expression – a suppression reagent. United States Patent. (Patent #: US 7,622,456 B2) ( Patent date: June 8, 2010)

  4. 鄭恩加、張東杰、邱清旗。專一性抑制葡萄糖調節蛋白-78(Grp78)表現之RNA干擾(RNAi)序列、抑制藥劑及抑制方法。中華民國專利。專利案號: I-371285,核准日期: 201291日,專利權期: 201291日至2028110日。

  5. 鄭恩加、陳盈汝、張東杰。DSG3 分子於頭頸癌之臨床應用-預測癌症惡性程度及作為分子應用標的的方法與專一性抑制DSG3表現之RNA干擾序列運用方法。中華民國專利。(專利案號: 095140849,核准日期: 2012913)

類別

專利名稱

國別

專利號碼

發明人

專利權人

專利核准

    

國科會

計畫編號

(A)發明專利

Methods on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degrees of cancer, serving as a molecular target and using RNA jamming sequence on inhibition- specific of DSG3 expression _ a suppression method.

美國

US 7,622,456 B2

鄭恩加等

長庚大學

長庚醫院

Nov 24, 2009

NSC- 91-2314-B-182-058

NSC-92-2314-B-182-058

NSC-93-2314-B-182-058

(A)發明專利

Methods on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degrees of cancer, serving as a molecular target and using RNA jamming sequence on inhibition- specific of DSG3 expression _ a suppression reagent.

美國

US 7,732,594 B2

鄭恩加等

長庚大學

長庚醫院

Jun 8, 2010

NSC- 91-2314-B-182-058

NSC-92-2314-B-182-058

NSC-93-2314-B-182-058

(A)發明專利

Specific Grp78 expression- inhibition RNAi sequence, medicine thereof and method thereof _  a method for head and neck cancer

美國

US 7,825,100

B2

鄭恩加等

長庚大學

Nov 2, 2010

NSC-94-2320-B-182-042

NSC-94-2745-B-182-004-URD

NSC-95-2745-B-182-004-URD

(A)發明專利

Specific Grp78 expression- inhibition RNAi sequence, medicine thereof and method thereof _ specific Grp78-RNAi sequence.

美國

US 7,829,695 B2

鄭恩加等

長庚大學

Nov 9, 2010

NSC-94-2320-B-182-042

NSC-94-2745-B-182-004-URD

NSC-95-2745-B-182-004-URD

(A)發明專利

專一性抑制葡萄糖調節蛋白78(Grp78)  表現之RNA干擾(RNAi)序列、抑制藥劑及抑制方法

中華民國

I-371285

鄭恩加等

長庚大學

Sep 1, 2012

(2012.09.01~

2028.01.10)

NSC-94-2320-B-182-042

NSC-94-2745-B-182-004-URD

NSC-95-2745-B-182-004-URD

(A)發明專利

DSG3 分子於頭頸癌之臨床應用-預測癌症惡性程度及作為分子應用標的的方法與專一性抑制 DSG3表現之RNA干擾序列運用方法

中華民國

95140849

鄭恩加等

長庚大學

長庚醫院

Sep 13, 2012

NSC- 91-2314-B-182-058

NSC-92-2314-B-182-058

NSC-93-2314-B-182-058

 

瀏覽數  
  • 友善列印
  • 新增到收藏夾
  • 分享
將此文章推薦給親友
請輸入此驗證碼
Voice Play
更換驗證碼